Clinical Trials Browser

Not yet recruiting × Myelodysplastic Syndromes × 30 days × Clear all

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07528417 2026-04-14

MYELO-CAN:ABX

Phase 2 Not yet recruiting

75 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Neutropenia, Leukemia, Myeloid, Acute

NCT07153497 2026-04-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Phase 2 Not yet recruiting

132 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07469592 2026-04-13

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

Phase NA Not yet recruiting

165 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07254793 2026-04-07

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

Phase 1 Not yet recruiting

94 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Motor Activity, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05969821 2026-03-23

CHIS

Not yet recruiting

5,000 enrolled

LymphoidMyeloidOther hematologic neoplasm

VEXAS syndrome, Autoimmune Diseases, Hematologic Diseases, Immune System Diseases, Inflammation, Leukemia, Lymphoma, Lymphoproliferative Disorders, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases

Clinical Trials

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

MYELO-CAN:ABX

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

CHIS